tiprankstipranks
Allogene Therapeutics to present data on ALLO-316 at IKCS, SITC meetings
PremiumThe FlyAllogene Therapeutics to present data on ALLO-316 at IKCS, SITC meetings
18d ago
Allogene Therapeutics receives FDA RMAT designation for ALLO-316
Premium
The Fly
Allogene Therapeutics receives FDA RMAT designation for ALLO-316
25d ago
Is ALLO a Buy, Before Earnings?
Premium
Pre-Earnings
Is ALLO a Buy, Before Earnings?
25d ago
Allogene Therapeutics price target lowered to $14 from $35 at Canaccord
PremiumThe FlyAllogene Therapeutics price target lowered to $14 from $35 at Canaccord
4M ago
Allogene Therapeutics assumed with an Outperform at Oppenheimer
Premium
The Fly
Allogene Therapeutics assumed with an Outperform at Oppenheimer
4M ago
Allogene Therapeutics reports Q2 EPS (35c), consensus (35c)
Premium
The Fly
Allogene Therapeutics reports Q2 EPS (35c), consensus (35c)
4M ago
Allogene Therapeutics initiates Phase 2 cema-cel trial
PremiumThe FlyAllogene Therapeutics initiates Phase 2 cema-cel trial
5M ago
Allogene Therapeutics participates in a conference call with JPMorgan
Premium
The Fly
Allogene Therapeutics participates in a conference call with JPMorgan
5M ago
Allogene Therapeutics Enhances Leadership and Affirms Shareholder Decisions
Premium
Company Announcements
Allogene Therapeutics Enhances Leadership and Affirms Shareholder Decisions
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100